Page 111 - CIBEREHD2016-ENG

Most relevant scientific articles
• Fernandez-Calotti P., Casulleras O., Antolin M., Guarner F., Pastor-Anglada M. Galectin-4 interacts with the drug transporter human concentrative nucleoside transporter 3 to regulate its function. FASEB Journal. 2016;30(2):544-554.
• Catala A., Pastor-Anglada M., Caviedes-Cardenas L., Malatesta R., Rives S., Vega-Garcia N. et al. FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016;7(31):49786-49799.
• Grane-Boladeras N., Perez-Torras S., Lozano J.J., Romero M.R., Mazo A., Marin J.J.G. et al. Pharmacogenomic analyzis of the responsiveness of gastrointestinal tumor cell lines to drug therapy: A transportome approach. Pharmacological Research. 2016; 113:364-375.
• Grane-Boladeras N., Spring C.M., Hanna W.J.B., Pastor-Anglada M., Coe I.R.. Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir. Cellular and Molecular Life Sciences. 2016;73(23):4559-4575.
• Pérez-Torras S, Iglesias I, Llopis M, Lozano JJ, Antolín M, Guarner F et al. Transportome Profiling Identifies Profound Alterations in Crohn’s Disease Partially Restored by Commensal Bacteria.Journal of Crohn’s & colitis. 2016.
Hightlights
During 2016 we have reported new gene networks incorporating a variety of plasma membrane transporters which, as a whole, build up what we call the cellular transportome. The transportome is
tightly linked to a variety of intracellular machineries implicated in cell proliferation, including drug and druggable targets. These networks might be critically altered in inflammatory diseases, such as Crohn’s disease, being these alterations partially reversed by commensal bacteria. They also incorporate a subset of genes and proteins, the purinome, similarly altered in inflammation and cancer. Moreover, a major progress has been made by applying MYTH (Membrane Yeast Two Hybrid) to unveil novel partner proteins for selected membrane transporters thus defining their interactome. MYTH has been used to identify hENT2 protein partners which build up functional heteromers in the cell nucleus, thereby determining nucleotide availability and cell cycle progression. This opens for the forthcoming years the possibility of analyzing
how this machinery might contribute to oncogenesis. Galectin-4 has also been identified, albeit with more classical approaches (proteomics) as a partner protein of the purine and thiopurine transporter hCNT3, being Galectin-4 able to regulate its function in a way that might be relevant to anti-inflammatory drug bioavailability. The use of MYTH to undertake further analysis of selected membrane proteins interactome has been recently awarded a Fundación Ramón Areces project (granted in 2016) to be developed during the forthcoming three years, starting January 2017. Most of these studies have also involved researchers from CIBEREHD. An inter-CIBER collaboration (CIBEREHD – CIBERER), has also helped to understand how combined therapies involving selected tyrosine kinase inhibitors (i.e. FLT3 inhibitors) and conventional anticancer drugs (i.e. cytarabine) might compromise drug responsiveness depending upon drug administration protocols, simply because tyrosine kinase inhibitors might eventually impact on the cellular pathways associated with drug action.
EHD
research Groups 111